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Abstract
Background: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus
Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and
reduces the adherence to HAART.
The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule.
Methods: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU
daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA <50 copies/
ml in all patients; HCV-RNA 28, 3  106 copies/ml.
Results: At 48 weeks, 10 patients (20%) achieved a biochemical and virological response according
to an intention to treat analysis.
Twenty four patients (48%) underwent a drop-out mainly by side effects related to overlapping
toxicity of interferon and antiretroviral therapy. All the patients, who responded to the treatment,
showed a fast relapse one month after the end of treatment.
Conclusion: Although our results demonstrated a very poor outcome and a bad tolerance to
interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk
for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use
of ribavirin.
Background
HIV – hepatitis C virus (HCV) coinfection is common and
affects more than one third of all HIV infected persons
worldwide. Prevalence among risk categories varies ac-
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cording to shared risk factors for transmission, mainly In-
travenous Drug Use (IDU) and haemophiliacs [1].
Chronic HCV infection seems to accelerate the course of
HIV disease, resulting in a worsened clinical and immu-
nological progression[2]. At the same time, several studies
suggest that HIV disease modifies the natural history of
HCV infection, leading to a faster course of progression
from active hepatitis to cirrhosis, to end stage liver disease
and death [3–6]. HCV infection mimics opportunistic dis-
eases because its natural history is significantly accelerated
in HIV patients [7].
Since 1996 Higly Active Antiretroviral therapy (HAART)
has slowed the progression of HIV disease and decreased
the rate of HIV associated mortality[8].
Because the prognosis of HIV disease has been modified
by HAART, the need to treat HCV coinfection became a
significant issue. However, few studies have described the
use of Interferon- for treatment of chronic HCV infection
in HIV infected patients. The reports of Boyer [9] and Mar-
riot [10] showed a poor sustained response. In the largest
up to now published study, Soriano [11] described that
the 20% of patients achieved a sustained virological re-
sponse; in this study Interferon- appeared to be well tol-
erated. These results have been obtained with a thrice
weekly (TIW) Interferon schedule. Strategies to improve
the response to therapy are needed to modify the progres-
sion of HCV related liver diseases. Combination therapy
with Interferon alpha 2b and ribavirin (RBV) is effective in
immunocompetent patients, at least in 60% of those
achieving an end of treatment virological response (ETR)
and in 45% showing a sustained virological response
(SVR) 6 months after stopping IFN and RBV(12, 13). In
mono infected patients with severe chronic hepatitis the
percentage of SVR is about 35% [14]. The need for a more
aggressive therapy in HIV-HCV patients is justified by the
worsened clinical course. A significant problem in the
treatment of coinfection arises from the complexity of
both HAART and standard of care regimen for HCV hepa-
titis. Indeed, the use of combination therapy with IFN
plus ribavirin may induce drug interactions, (in vitro stud-
ies have demonstrated that ribavirin could affect intracel-
lular phosphorylation of deoxynucleoside, mainly AZT,
[15] leading to a reduced therapeutic effect), increases the
pill burden, reducing the adherence to HAART, and the
risk of mithocondrial toxicity (16, 17). In our previous
study performed in immunocompetent patients we dem-
onstrated that daily IFN administration is more effective
than TIW[18].
On this basis we have attempted to treat coinfected pa-
tients with a daily interferon schedule, in order to improve
the percentage of clinical response.
The aim of this pilot study is to evaluate the efficacy and
safety of an aggressive daily schedule of 3 MU  Interferon
in the treatment of HCV related chronic hepatitis in pa-
tients infected with HIV.
Methods
Fifty caucasian HIV-seropositive patients co-infected with
HCV were enrolled in a study on the tolerance and efficacy
of a daily administration of interferon- for the treatment
of active chronic hepatitis C. Patients were eligible for the
study if they presented with detectable HCV RNA in se-
rum, elevated serum alanine amino transferase (ALT) and
a histological fibrosis score on liver biopsy of  1. Histo-
logical necrotic inflammatory activity and fibrosis, were
assessed quantitatively using the modified Knodell histo-
logical activity index [19] on a liver biopsy performed
within 6 months prior entry into the study. Exclusion cri-
teria were the presence of circulating Hbs antigen, a self re-
ported daily intake of alcohol > 40 gr, haemolytic disease,
decompensated cirrhosis, auto-immune hepatitis, preg-
nancy and a diagnosis of opportunistic infections oc-
curred in the 6 months before entry into the study. All
patients gave informed consent prior to the inclusion in
the study. The baseline demographic characteristics of the
patient population are described in Table 1. Seventy seven
percent of the patients had a past history of injecting drug
use, with a mean duration of drug use of 18.2  3.3 years.
Forty five of the patients (91%) had been receiving antiret-
roviral drugs for 3.0  1.5 years at the time of inclusion
into the study. Four of the antiretroviral-treated patients
(9%) were receiving a combination of two nucleoside re-
verse transcriptase inhibitors (NRTI). The other patients
were taking a triple drug combination therapy including
two NRTI and a protease inhibitor, indinavir (n = 36) and
Table 1: Baseline demographic characteristics of the patients
Number of patients 50
Males 42
females 8
Age (mean) 37
Past history of alchol abuse (%) 28 (56)
Estimated duration of HCV 
infection(months) [mean  SD]
29,2  13,1
Antiretroviral Therapy (%) 45 (91)
HCV genotypes
1b 16
2–3 25
49
Mean CD4 cells/mmc count (range) 515 (179–1135)
HIV-RNA <50 copie/ml in all patients
HCV-RNA (mean) 28,3  106 copies/ml
Knodell score 7  3
Cirrhosis (%) 7 (14)BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/17
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saquinavir (n = 5). All patients exhibited a positive PCR
for HCV RNA in serum. Sixteen (32%) carried virus of
genotype la and lb; genotypes 2–3a were found in twenty
five (50%) whereas genotype 4 was found in nine patients
(18%). All patients (100%) were naive to IFN. Upon in-
clusion into the study, all patients were given 3 MU of 
IFN 2a daily for 48 weeks. Interferon dose was reduced,
when necessary to 1,5 MU daily.
Surrogate markers for hepatitis C and HIV disease
Serum levels of alanine amino transferase (ALT normal 
39 IU/l), aspartate aminotransferase (AST; normal,  34
IU/l), gamma glutamyl transferase (GGT normal,  53 IU/
l) and bilirubin (normal  1.10 mg/l) were measured us-
ing standard methods. Serum HCV RNA was measured by
a qualitative PCR assay (COBAS Amplicor HCV, version
2.0, limit of detection of 100 copies/milliliter), and quan-
titative HCV RNA was evaluated by a branched DNA sig-
nal amplification assay test (Quantiplex HCV RNA 2.0,
Chiron, Emeryville, California, USA; range of detection,
200.000 – 120.000.000 geq/ml). The HCV genotype was
determined by hybridization of biotin-labelled PCR prod-
ucts to oligonucleotide probes bound to nitrocellulose
membrane strips (Inno-Lipa; Innogenetics, Brussels, Bel-
gium). Absolute numbers of CD4 cells in whole blood
were determined by flow cytometry. Serum levels of HIV-
RNA were determined by the branched DNA test (Quan-
tiplex HIV RNA 2.0; Chiron; threshold: 50 copies/ml).
Both HIV-RNA levels and CD4 cells count were measured
at baseline and after four, eight, twelve weeks and, subse-
quently every three months. Hepatic inflammation and fi-
brosis were graded using the modified Knodell
histological activity index. The inflammation score was
determined by combining the first free index scores: por-
tal, periportal and lobular inflammation. The inflamma-
tion score has a range from 0 to 18; the higher score
indicates more severe histological abnormalities. The de-
grees of fibrosis were: 0, no fibrosis; 1, portal fibrosis; 3,
bridging fibrosis and 4 cirrhosis.
End Points
The primary efficacy end point was a sustained virological
response (SVR) defined as a lack of detectable HCV-RNA
in the serum at 24 weeks after the treatment was complet-
ed. A secondary end point was the presence of a end of
treatment response (ETR), defined as the absence of se-
rum HCV-RNA at the end of 48 weeks of therapy. Adverse
events, both clinical and laboratory, were checked at every
scheduled visit.
Statistical analysis
Analysis of results was carried out using an as treated
(where only patients carrying on treatment were includ-
ed) and an intent to treat analysis, where missed data were
considered as failure. Quantitative variables to compare
baseline and follow-up values from individual patients
were compared by using the t test for paired samples, after
log transformation, where appropriate. Results are ex-
pressed as mean  SD.
Results
We did not observe a reduction neither in absolute count
nor in percent of CD4 cells. Only transient blips of HIV
viremia were recorded with values less than 1000 copies/
ml.
The mean ALT value in the study population were 169 
129 at baseline. The necrotic-inflammatory and fibrosis
scores. were 7  3 and 2  1, respectively. Seven out of the
50 patients showed histological evidence of cirrhosis
(14%). At baseline HCV viremia was 28.3  36.6  106 ge-
nome equivalents (geq)/ml. Only twenty six individuals
completed 48 weeks of treatment without any serious or
potentially life-threatening adverse events; there were no
drug-related deaths. The mean duration of therapy was 23
 19 weeks.
After 24 weeks of therapy, the mean levels of ALT de-
creased to 131  6 1 U I / l  ( p = NS) .  A t  t h i s  t i m e  H C V
viremia was 9.2  12.4  106 genome equivalents (geq)/
ml (p = 0.66). The as treated analysis showed a percentage
of responders of 58% (29/50). The intention to treat anal-
ysis showed a percentage of responders of 44% (22/50).
After 48 weeks of therapy, the mean levels of ALT de-
creased to 95  61 UI/l (p = NS). At this time HCV viremia
was 1.4  1.6  106 genome equivalents (geq)/ml (p =
0.07). The percentage of responders decreased to 38%
(19/50) according to an as treated analysis, and to 20%
(10/50) according to an intention to treat analysis.
Among end of treatment virological responders 6 patients
were genotype 3A, while 4 were genotype 1. One of them
was cirrhotic.
All out of the responders showed a rapid relapse within
one months after completing the treatment : Alt mean val-
ue was 79  75 UI/ml (p = NS) and mean HCV-RNA value:
39.07  20,22  106 genome equivalents (geq)/ml (p =
NS). (table 2). Thus, the observed SVR rate was 0%.
Side effects
Among patients who completed treatment, 4 had interfer-
on dose reduction due to leukopenia; 2 out of the re-
sponder ones.
A total of 24 patients (48%) discontinued the treatment
because of therapy related side effects. The most frequent
adverse event was depression, occurred in 8 patients
(33%). No patients were on antidepressant at the initia-
tion of interferon. Nobody received a specific treatmentBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/17
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for depression, which improved rapidly after discontinua-
tion of interferon. Malaise, fatigue and fever, so strong to
stop the therapy, were recorded in 8 patients (33%). Leu-
kopenia (absolute neutrophil count < 750/mmc) oc-
curred in 6 patients (25%) and did not improve after IFN
dose reduction. Two patients were lost to follow up (8%).
Adherence to interferon therapy was difficult even in pa-
tients who did not experience side effects or did not neces-
sitate a dose reduction. While patients were receiving IFN
treatment, they have shown a reduced acceptance to
antiretroviral drugs. (table 3) This means that the discom-
fort due to the concomitant treatment impaired the capac-
ity to be adherent to antiretroviral drugs, leading to an
increase of missed doses.
Discussion
HIV coinfection has been considered until a couple of
years ago as an exclusion criteria in all the controlled trials
on efficacy of interferon used as monotherapy and in
combination with ribavirin. So, available data comes out
from pilot studies or comparative studies versus HIV un-
infected patients. Three hundred and eighty eight patients
have been enrolled in the 12 studies published as full pa-
pers on interferon monotherapy. None of these studies
was placebo controlled; both interferon alfa 2a and 2b
were used with doses ranging from 1 million units three
times per week to 9 MIU daily. Arbitrarily cumulating
these data, end of treatment response was obtained in
28% of treated patients and sustained response in 16%.
Ten per cent of patients dropped out[20]. In the largest
published study, Soriano et al described how 20% of pa-
tients achieved a sustained virological response [11].
Summarizing the five studies, comparing sustained re-
sponse rate in HIV seropositives and seronegatives we can
identify a slightly lower rate of sustained response in HIV
seropositives in all the trials; however this difference did
not reach statistical significance in any of them [20].
Analyzing all these studies, ranked according to the year of
publication, we can identify a sharp decrease in the rate of
sustained response in the studies published in the last 3
years [21–23]. The change in response rate to interferon
monotherapy could probably be related to a change of the
kind of patients which have been included in the HAART
era. Recently have become to be treated the most difficult
patients with advanced fibrosis, unfavourable genotypes,
high HCV viremia and lower CD4 counts.
Actually the standard of care for chronic hepatitis C in im-
munocompetent patients has become the combination
therapy of interferon and ribavirin, but so far there are
only few published data obtained in HIV-HCV coinfected
patients with an impressive difference of sustained re-
sponse rate among the studies [24][17][25].
However, the use of combination therapy with IFN plus
ribavirin may induce drug interactions, (in vitro studies
have demonstrated that ribavirin could affect intracellular
phosphorylation of deoxynucleoside, mainly AZT,[15]
and d4t, leading to a reduced therapeutic effect), increases
the pill burden, compromising the adherence to HAART,
and the risk of mithocondrial toxicity.
Indeed, recent reports suggest that addition of ribavirin to
an NRTI based antiretroviral therapy may increase the risk
of life-threatening lactic acidosis [16,17].
The finding that NRTIs may interfere with mitochondrial
DNA synthesis led to many studies evaluating these effects
in vitro. These studies suggested a ranking of
ddC>ddI>d4T>3TC>AZT>ABC for effects on mitochon-
drial polymerase gamma [26,27].
Table 2: Laboratory findings at 24 weeks, end of treatment and one month after end of treatment.
Baseline 24 weeks P End of treatment 
(ETR) 12 months
P 1 month after end of 
treatment
p
ALT UI/ml (mean  SD) 169  129 131  61 NS 95  61 NS 79  75 NS
HCV-RNA  106geq/ml 
(mean  SD)
28.3  36.6 9.2  12.4 0.66 1.4  1.6 0.07 39.07  20.22 NS
Table 3: Side effects leading to interruption
Number of patients 
(total n = 24)
Percentage
Depression 8 33%
Malaise, fatigue 4 16%
Fever 4 16%
Leukopenia 6 25%
Lost to follow up 2 8%BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/17
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Because each NRTI has a different affinity for mitochon-
drial polymerase gamma, they could have a different ca-
pacity for inducing liver toxicity.
Hence, the choice of treatment of both hepatitis C and
HIV must be oriented toward drugs with lower overlap-
ping toxicity, mainly if ribavirin is used. This approach
could be useful to increase the safety of therapy of coinfec-
tion and to avoid cases of fatal lactic acidosis. The use of
interferon alone may reduce the incidence of such therapy
related adverse events. In this setting we tried to use an ag-
gressive daily interferon schedule (3 MU daily) which in
immunocompetent patients gave us a good sustained re-
sponse rate [18].
In the present study we report an ETR rate of 20% and a
SVR rate of 0%, with all patients relapsing one month af-
ter stopping the therapy. The ETR rate is comparable to
that observed either in immunocompetent patients or in
HIV-HCV coinfected patients treated with interferon
alone three times weekly. This percentage of ETR observed
in our study has been reduced by the high incidence of
side effects due to the overlapping toxicity of both antiret-
roviral and interferon therapy. The SVR was 0% and may
probably be influenced, as observed in other studies with
low SVR rate [21–23], by the lack of immune-clearance
which regulates the late phase of viral decay. Indeed the
more rapid is the viral decay, the higher is the probability
of SVR [28].
Although a CD4 cell count threshold of less than 200
cells/mmc has been reported to reduce the likelihood of
SVR, this has not been observed in our patients who did
not respond, in spite of having more than 200 CD4 cells/
mmc. Most of the adverse events encountered in this
study were similar to those reported in HIV seronegative
immunocompetent patients, but they were emphasized
by the concomitant administration of antiretrovirals
which made the patients intolerant to both treatment, re-
sulting in a very high drop out rate.
So far the optimal treatment schedule for HCV has not yet
been established in co-infected patients. Several studies
are ongoing to determine if the outcome could be im-
proved by the use of pegylated interferon plus ribavirin,
with promising preliminary results[29]. Data on pegylat-
ed interferon alone in HIV patients are actually lacking.
Although our results have demonstrated a very poor out-
come with interferon monotherapy, this approach should
not be completely dropped out, especially using PEG In-
terferon, mainly in patients at high risk for side effects and
in those with cirrhosis who do not tolerate or are at in-
creased risk for the use of ribavirin. This strategy could be
useful to increase the safety of therapy of coinfection and
to avoid cases of severe liver toxicity and lactic acidosis.
However, depending upon the baseline CD4 cell count
level, in patients with more than 350 CD4+/mmc, hepati-
tis treatment should precede antiretroviral therapy to re-
duce the overall risk of toxicity.
References
1. Staples CT Jr, Rimland D, Dudas D: Hepatitis C in the HIV (hu-
man immunodeficiency virus) Atlanta V.A. (Veterans Affairs
Medical Center) Cohort Study (HAVACS): the effect of
coinfection on survival. Clin Infect Dis 1999, 29(1):150-4
2. Piroth L, Duong M, Quantin C, et al: Does hepatitis C virus co-in-
fection accelerate clinical and immunological evolution of
HIV-infected patients? AIDS 1998, 12(4):381-8
3. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert
JJ: Natural history of hepatitis C virus infection in multitrans-
fused hemophiliacs: effect of coinfection with human immu-
nodeficiency virus. The Multicenter Hemophilia Cohort
Study. J Acquir Immune Defic Syndr 1993, 6(6):602-10
4. Martin P, Di BA, Kassianides C, Lisker-Melman M, Hoofnagle J: Rap-
idly progressive non-A, non-B hepatitis in patients with hu-
man immunodeficiency virus infection. Gastroenterology 1989,
97(6):1559-61
5. Benhamou Y, Di MV, Bochet M, et al: Factors affecting liver fibro-
sis in human immunodeficiency virus-and hepatitis C virus-
coinfected patients: impact of protease inhibitor therapy.
Hepatology 2001, 34(2):283-7
6. Rockstroh J, Woitas R, Spengler U: Human immunodeficiency vi-
rus and hepatitis C virus coinfection.  Eur J Med Res 1998,
3(6):269-77
7. Sulkowski MS, Mast EE, Seeff LB, Thomas DL: Hepatitis C virus in-
fection as an opportunistic disease in persons infected with
human immunodeficiency virus. Clin Infect Dis 2000, 30(Suppl
1):S77-84
8. Palella F, Delaney K, Moorman A, et al: Declining morbidity and
mortality among patients with advanced human immunode-
ficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med 1998, 338(13):853-60
9. Boyer N, Marcellin P, Degott C, et al: Recombinant interferon-al-
pha for chronic hepatitis C in patients positive for antibody
to human immunodeficiency virus. Comite des Anti-Viraux.
J Infect Dis 1992, 165(4):723-6
10. Marriott E, Navas S, del RJ, et al: Treatment with recombinant al-
pha-interferon of chronic hepatitis C in anti-HIV-positive pa-
tients. J Med Virol 1993, 40(2):107-11
11. Soriano V, Garcia-Samaniego J, Bravo R, et al: Interferon alpha for
the treatment of chronic hepatitis C in patients infected with
human immunodeficiency virus. Hepatitis-HIV Spanish
Study Group. Clin Infect Dis 1996, 23(3):585-91
12. McHutchison J, Gordon S, Schiff E, et al: Interferon alfa-2b alone
or in combination with ribavirin as initial treatment for
chronic hepatitis C. Hepatitis Interventional Therapy
Group. N Engl J Med 1998, 339(21):1485-92
13. Poynard T, Marcellin P, Lee S, et al: Randomised trial of interfer-
on alpha2b plus ribavirin for 48 weeks or for 24 weeks versus
interferon alpha2b plus placebo for 48 weeks for treatment
of chronic infection with hepatitis C virus. International Hep-
atitis Interventional Therapy Group (IHIT).  Lancet 1998,
352(9138):1426-32
14. Poynard T, McHutchison J, Davis G, et al: Impact of interferon
alfa-2b and ribavirin on progression of liver fibrosis in pa-
tients with chronic hepatitis C. Hepatology 2000, 32(5):1131-7
15. Vogt M, Hartshorn K, Furman P, et al: Ribavirin antagonizes the
effect of azidothymidine on HIV replication.  Science 1987,
235(4794):1376-9
16. Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial
toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001,
357(9252):280-1
17. Sauleda S, Juarez A, Esteban J, et al: Interferon and ribavirin com-
bination therapy for chronic hepatitis C in human immuno-
deficiency virus-infected patients with congenital
coagulation disorders [In Process Citation]. Hepatology 2001,
34(5):1035-40
18. Bruno MD R, Sacchi P, Maffezzini E, Zara F, Brunetti E, Filice C, Patru-
no SFA, Filice G: Daily Interferon regimen for chronic hepatitisBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/17
Page 6 of 6
(page number not for citation purposes)
C. A prospective randomized study. Clin Drug Invest 1999, 18:11-
16
19. Knodell RGIK, Black WC: Formulation and application of a nu-
merical scoring system for assessing histological activity in
asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-
435
20. Bonacini M, Puoti M: Hepatitis C in patients with human immu-
nodeficiency virus infection: diagnosis, natural history, meta-
analysis of sexual and vertical transmission, and therapeutic
issues. Arch Intern Med 2000, 160(22):3365-73
21. Prestileo T, Mazzola G, Di LF, et al: Response-adjusted alpha-in-
terferon therapy for chronic hepatitis C in HIV-infected pa-
tients. Int J Antimicrob Agents 2000, 16(3):373-8
22. Bruno R, Sacchi P, Filice C, Filice G: Aggressive daily interferon
therapy in HIV-HCV coinfected patients. J Acquir Immune Defic
Syndr 2000, 25(4):372-3
23. Hayashi K, Fukuda Y, Nakano I, et al: Poor response to interferon
treatment for chronic hepatitis C in human immunodefi-
ciency virus-infected haemophiliacs.  Haemophilia 2000,
6(6):677-81
24. Landau A, Batisse D, Piketty C, et al: Long-term efficacy of com-
bination therapy with interferon-alpha2b and ribavirin for
severe chronic hepatitis C in HIV-infected patients [In Proc-
ess Citation]. AIDS 2001, 15(16):2149-55
25. Nasti G, Di GG, Tavio M, et al: Chronic hepatitis C in HIV infec-
tion: feasibility and sustained efficacy of therapy with inter-
feron alfa-2b and tribavirin. AIDS 2001, 15(14):1783-7
26. Kakuda T: Pharmacology of nucleoside and nucleotide re-
verse transcriptase inhibitor-induced mitochondrial toxicity.
Clin Ther 2000, 22(6):685-708
27. White A: Mitochondrial toxicity and HIV therapy. Sex Transm
Inf 2001, 77:158-173
28. Wiley T, Briedi L, Lam N, Layden T: Early HCV RNA values after
interferon predict response. Dig Dis Sci 1998, 43(10):2169-72
29. Soriano VG-SJ, Perez-Olmeda M, Barreiro P, Nunez M, Rodriguez-
Rosado R: Pegylated Interferon plus ribavirin for the treat-
ment of chronic hepatitis C in HIV infected patients. 1st IAS
Conference on HIV pathogenesis and treatment. Buenos Aires July 8–11.
2001
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/2/17/prepub
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com